Emmaus Life Sciences Inc (PK:EMMA)

Business Focus: Biotechnology & Medical Research

Apr 15, 2024 04:07 pm ET
Emmaus Life Sciences Reports Delayed Filing of Annual Report
TORRANCE, Calif., April 15, 2024 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, reported today that the filing of its Annual Report on Form 10-K for the year ended December 31, 2023 will be delayed.
Feb 02, 2024 09:00 am ET
Emmaus Life Sciences Receives Marketing Authorization for Puerto Rico
TORRANCE, Calif., Feb. 2, 2024 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a leader in sickle cell disease (SCD) treatment, today announced that it has received marketing authorization from the Puerto Rico Department of Health for Endari® (L-glutamine oral powder). This approval marks a significant milestone in Emmaus' mission to improve the lives of people with SCD around the world and provides access to this important therapy for the patients living with SCD in Puerto Rico.  In addition, Endari® is approved in the United States, Israel, United Arab Emirates, Kuwait, Qatar, Ba
Nov 14, 2023 08:30 am ET
Emmaus Life Sciences Reports Q3 2023 Financial Results
TORRANCE, Calif., Nov. 14, 2023 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported on its financial condition and results of operations as of and for the three and nine months ended September 30, 2023.
Jul 13, 2023 03:10 pm ET
Emmaus Life Sciences Receives Marketing Authorization for Endari® in Oman
Sickle Cell Disease Treatment Commercially Available in Five GCC Countries
May 31, 2023 02:11 pm ET
Emmaus Life Sciences Receives Endari® Marketing Authorization from the Bahrain NHRA
TORRANCE, Calif., May 31, 2023 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a leader in sickle cell disease treatment, announced today that it has received a Medicine Registration Certificate (DRN-10164/23) from the Bahrain National Health Regulatory Authority (NHRA) granting marketing authorization for the commercial distribution and sale of Endari® in the Kingdom of Bahrain.  
May 15, 2023 09:30 am ET
Emmaus Life Sciences Reports Q1 2023 Financial Results and Provides Business Update
TORRANCE, Calif., May 15, 2023 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported on its financial condition and results of operations as of and for the three months ended March 31, 2023.
Apr 03, 2023 11:00 am ET
Emmaus Life Sciences Provides Interim Shipment Data
TORRANCE, Calif., April 3, 2023 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a leader in sickle ell disease treatment, announced today preliminary results for the 3 months ended March 31, 2023.
Mar 31, 2023 04:15 pm ET
Emmaus Life Sciences Reports 2022 Financial Results and Provides Business Update
TORRANCE, Calif., March 31, 2023 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported its results of operation for the year ended December 31, 2022 and an update on recent activities.
Dec 20, 2022 09:00 am ET
Dr. Niihara Meets with Local Indian Governor
Cites Large, Unserved Needs of Sickle Cell Disease Patients 
Dec 19, 2022 09:00 am ET
Dec 07, 2022 01:25 pm ET
Endari® Receives Kuwaiti Marketing Authorization
Kuwait is Third Gulf Cooperation Council Country to Approve Endari®
Nov 17, 2022 08:30 am ET
Nov 14, 2022 06:42 pm ET
/C O R R E C T I O N -- Emmaus Life Sciences, Inc./
In the news release, Emmaus Life Sciences Reports Q3 2022 Financial Results and Provides Business Update, issued 14-Nov-2022 by Emmaus Life Sciences, Inc. over PR Newswire, we are advised by the company that verbiage in the Recent Highlights quotation has been updated. The complete, corrected release follows:
Nov 14, 2022 05:16 pm ET
Emmaus Life Sciences Reports Q3 2022 Financial Results and Provides Business Update
TORRANCE, Calif., Nov. 14, 2022 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported on its results of operations and financial condition as of and for the three and nine months ended September30, 2022 and provided a business update.
Sep 28, 2022 06:30 am ET
Aug 15, 2022 04:30 pm ET
Emmaus Life Sciences Reports Q2 2022 Financial Results and Provides Business Update
TORRANCE, Calif., Aug. 15, 2022 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported financial results for the three and six months ended June 30, 2022 and provided a business update.
Jul 12, 2022 10:00 am ET
Emmaus Life Sciences Announces Engagement of Strategic Business Relations and Professional Services Advisor
Acorn Management Partners Will Develop and Implement a Market Awareness Program Targeting Financial Professionals
Jun 24, 2022 08:35 am ET
Life Sciences Investor Forum Presentations Now Available for On-Demand Viewing
Virtual Investor Conferences, the leading proprietary investor conference series, today announced that the presentations from the June 23rd Life Sciences Investor Forum are now available for on-demand viewing. REGISTER NOW OR LOGIN AT:...
Jun 21, 2022 04:21 pm ET
UPDATE - Life Sciences Investor Forum: Company Executives Present Live June 23rd 
Virtual Investor Conferences, the leading proprietary investor conference series, in partnership with Zacks Small-Cap Research, today announced the agenda for the upcoming Life Sciences Investor Forum to be held on June 23rd. Individual investors,...
May 13, 2022 08:23 am ET
Emmaus Life Sciences Reports Q1 2022 Financial Results and Provides Business Update
TORRANCE, Calif., May 13, 2022 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported financial results for the three months ended March 31, 2022 and provided a business update.
Apr 26, 2022 08:23 am ET
Emmaus Life Sciences to Present at Investor Conferences in May
TORRANCE, Calif., April  26, 2022  /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today announced participation in the following investor conferences in May:
Apr 11, 2022 08:23 am ET
Emmaus Life Sciences Announces Launch of Full-Service Telehealth Solution
Platform Providers Will Handle On-line Prescribing, Dispensing and Delivery of Endari®
Apr 07, 2022 08:23 am ET
Emmaus Life Sciences Presented Positive Real-World Data on the Efficacy of Endari® in Preventing Acute Complications from Sickle Cell Disease at the 62nd Annual Scientific Meeting of the British Socie
Sickle Cell Patients Treated With Endari® had Statistically Significantly Fewer Vaso-Occlusive Events and Hospitalizations Through 72 Weeks Follow-up, Versus Baseline
Mar 31, 2022 05:24 pm ET
Emmaus Life Sciences Reports 2021 Financial Results and Provides Business Update
TORRANCE, Calif., March 31, 2022 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported financial results for the year ended December 31, 2021 and an update on recent activities.
Mar 29, 2022 08:23 am ET
Emmaus Life Sciences Announces Endari® To Be Added to the Florida Medicaid Preferred Drug List
Florida Joins Other States in Eliminating the Need for Prior Authorization for Medicaid Patients
Mar 23, 2022 08:23 am ET
Emmaus Life Sciences Receives U.A.E. Marketing Authorization for Endari®
TORRANCE, Calif., March 23, 2022 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA) a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today announced the approval of its application for marketing authorization of Endari® from the United Arab Emirates (U.A.E.) Ministry of Health after a five-month review of the company's marketing authorization application. During the review period, Endari was available in the U.A.E. on a named patient, or early access, basis only.
Mar 04, 2022 07:23 am ET
Emmaus Life Sciences' Real World Data on Endari® Accepted for E-Poster at the 62nd Annual Scientific Meeting of the British Society for Haematology
TORRANCE, Calif., March 4, 2022 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today announced that real world data on Endari®, the company's prescription-grade L-glutamine oral powder for the treatment of sickle cell disease, has been accepted for an e-poster at the 62nd Annual Meeting of the British Society for Haematology (BSH) to be held April 3-5, 2022 at the Manchester Central in Manchester, England and virtually.
Jan 04, 2022 07:23 am ET
Emmaus Life Sciences to Present at the H.C. Wainwright BioConnect Conference
TORRANCE, Calif., Jan. 4, 2022 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today announced that Yutaka Niihara, M.D., M.P.H, Chairman and Chief Executive Officer of Emmaus, will present a company overview at the H.C. Wainwright BioConnect Conference, being held virtually, January 10-13, 2021.
Dec 20, 2021 07:35 am ET
Life Sciences Companies Investor Presentations Now Available for On-Demand Viewing
NEW YORK, Dec. 20, 2021 /PRNewswire/ -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced that the presentations from the December 16th Life Sciences Virtual Investor Conference are now available for on-demand viewing.
Dec 20, 2021 07:35 am ET
Life Sciences Companies Investor Presentations Now Available for On-Demand Viewing
Individual and institutional investors as well as advisors are invited to log-on to VirtualInvestorConferences.com to view presentations
Dec 14, 2021 07:35 am ET
Virtual Conference for Life Sciences Companies Broadcast Live December 16th
Company executives will share corporate vision and answer audience questions at VirtualInvestorConferences.com
Dec 14, 2021 07:23 am ET
Emmaus Life Sciences Presents Positive Transfusion Data from a Post-Hoc Analysis of its Phase 3 Clinical Study of Endari® in Patients With Sickle Cell Disease at the 63rd American Society of Hematolog
TORRANCE, Calif., Dec. 14, 2021 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today announced positive transfusion data from a post-hoc analysis of its phase 3 clinical study of Endari®, the company's prescription L-glutamine oral powder, in patients with sickle cell disease (SCD). The data was introduced in a poster presentation on Monday, December 13, 2021 at the 63rd American Society of Hematology (ASH) Annual Meeting and Exhibition at the Georgia World Congress Center in Atlanta,
Dec 09, 2021 11:19 am ET
Life Sciences Virtual Investor Conference: Company Executives Present Live December 16th
NEW YORK, Dec. 9, 2021 /PRNewswire/ -- Virtual Investor Conferences, the leading proprietary investor conference series, announced the agenda for its quarterly event for public and private companies, investors, and industry professionals from around the world. This day-long virtual event will showcase live company presentations and interactive discussions focused on the life sciences industry.
Dec 09, 2021 07:35 am ET
Emmaus Life Sciences to Webcast Live at Life Sciences Investor Forum on December 16th
TORRANCE, Calif., Dec. 9, 2021 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today announced that Yutaka Niihara, M.D., M.P.H., Chairman and Chief Executive Officer of Emmaus, will present live at VirtualInvestorConferences.com, at 12:30 pm ET on December 16th.     
Dec 06, 2021 07:23 am ET
Emmaus Life Sciences' Data on Endari® Accepted for Poster Presentation at the 63rd American Society of Hematology Annual Meeting & Exhibition
TORRANCE Calif., Dec. 6, 2021 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today announced that data on Endari®, the company's prescription L-glutamine oral powder for the treatment of sickle cell disease, has been accepted for a poster presentation at the 63rd American Society of Hematology (ASH) Annual Meeting and Exhibition, to be held December 11 - 14 live, at the Georgia World Congress Center in Atlanta, Georgia, and virtually.
Nov 12, 2021 07:23 am ET
Emmaus Life Sciences Reports Third Quarter Financial Results and Business Highlights
TORRANCE, Calif., Nov. 12, 2021 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported financial results for the quarter and nine months ended September 30, 2021.
Nov 11, 2021 07:23 am ET
Emmaus Life Sciences Announces Partnership with UpScript to Provide Telehealth Solutions to Sickle Cell Disease Patients
TORRANCE, Calif., Nov. 11, 2021 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA) a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today announced a partnership with UpScript IP Holdings, LLC. (UpScript), to offer telehealth solutions to sickle cell disease patients, expanding access to Endari®, Emmaus' prescription L-glutamine oral powder for the treatment of sickle cell disease.
Nov 08, 2021 07:30 am ET
Emmaus Life Sciences to Participate in the Q4 Virtual Investor Summit
Torrance, California--(Newsfile Corp. - November 8, 2021) - Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today announced that Yutaka Niihara, M.D., M.P.H., Chairman and Chief Executive Officer of Emmaus, will present a company overview at the Q4 Virtual Investor Summit on November 16, 2021 at 2:00 p.m. ET.
Nov 04, 2021 08:23 am ET
Emmaus Life Sciences Enters into Agreement with Asembia to Provide Expanded Patient Support Services
TORRANCE, Calif., Nov. 4, 2021 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today announced it has entered into an agreement with Asembia to provide expanded patient and provider support services in order to simplify access to Endari®, the Company's prescription L-glutamine oral powder for the treatment of sickle cell disease.
Oct 12, 2021 08:23 am ET
Emmaus Life Sciences Acquires Key Intellectual Property Rights to Novel IRAK4 Inhibitor From Kainos Medicine
TORRANCE, Calif., Oct. 12, 2021 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today announced the signing of an agreement with Kainos Medicine, Inc. (Kainos), granting Emmaus an exclusive license to patent rights, know-how and other intellectual property relating to Kainos' novel IRAK4 inhibitor, referred to as KM10544, for the treatment of cancers including leukemia, lymphoma and solid tumors. The license agreement expands upon the existing research and development collaborati
Sep 08, 2021 07:00 am ET
OTC Markets Group Welcomes Emmaus Life Sciences, Inc. to OTCQX
NEW YORK, Sept. 8, 2021 /PRNewswire/ -- OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 11,000 U.S. and global securities, today announced Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company, has qualified to trade on the OTCQX® Best Market. Emmaus Life Sciences, Inc. upgraded to OTCQX from the Pink® market.
Sep 02, 2021 08:45 am ET
Emmaus Life Sciences Reports Financial Results for the Six Months Ended June 30, 2021
TORRANCE, Calif., Sept. 2, 2021 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTC: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today announced financial results for the six months ended June 30, 2021. As a result, the company is now current in its Securities and Exchange Commission (SEC) reporting obligations.
Aug 17, 2021 08:45 am ET
Emmaus Life Sciences Announces Bahrain Temporary License of Endari®
TORRANCE, Calif., Aug. 17, 2021 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTC: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, announced today that on August 12, 2021, the National Health Regulatory Authority (NHRA) of the Kingdom of Bahrain approved a Temporary License for Importation of Pharmaceutical Product for Endari.® The Pharmaceutical Products Regulation Department of the NHRA is responsible for ensuring the quality, safety, and efficacy of pharmaceutical products in the Kingdom of Bahrain. Endari®, Emmaus' prescription grade
Jul 22, 2021 09:00 am ET
Emmaus Life Sciences Provides Interim Sales Information
TORRANCE, Calif., July 22, 2021 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTC: EMMA), a leader in sickle cell disease treatment, announced today preliminary sales results for the six months ended June 30, 2021.
Jul 15, 2021 09:00 am ET
Emmaus Life Sciences Announces Submission of Endari® Marketing Authorization Application in Kuwait
TORRANCE, Calif., July 15, 2021 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTC: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, announced today the submission of its application for Marketing Authorization (MA) for Endari® to the Kuwait Drug and Food Control (KDFC).  This is the first step in the registration of Endari® by the KDFC, which is responsible for the registration of pharmaceutical products in Kuwait.  The KDFC has accepted Emmaus's request for fast-track review of Endari®, which is expected to take not more than twelve month
Jun 15, 2021 11:21 am ET
Emmaus Life Sciences Announces Submission of Marketing Authorization Application to Swissmedic Ideogen, A.G. to Manage Early Access Program
TORRANCE, Calif., June 15, 2021 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTC: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, announced today it has received confirmation from the Swiss Agency for Therapeutic Products (Swissmedic) of Emmaus' application for Marketing Authorization (MA) for Endari® in Switzerland. Swissmedic is responsible for the authorization and supervision of therapeutic products in Switzerland. In November 2020, Swissmedic granted Endari® orphan drug status.
Jan 27, 2021 10:30 am ET
Emmaus Life Sciences Reports Increase in Sales Volume in 2020
TORRANCE, Calif., Jan. 27, 2021 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTC: EMMA), a leader in the treatment of sickle cell disease, reports that it sold 25,947 boxes of Endari® in 2020 compared to 24,797 boxes in 2019, an increase of 5%. Emmaus is providing this information in advance of the filing of its Quarterly Reports on Form 10-Q for the first, second and third quarters of 2020 and Annual Report on Form 10-K for the year ended December 31, 2020.
Jan 25, 2021 11:13 am ET
Emmaus Life Sciences Reports Annual Financial Results for 2019 and Provides Business Review
TORRANCE, Calif., Jan. 25, 2021 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTC: EMMA), a leader in the treatment of sickle cell disease, reported today its financial results for the year ended December 31, 2019 and its restated financial results for the year ended December 31, 2018. As previously disclosed in the  Current Report on Form 8-K filed with the Securities and Exchange Commission ("SEC") on July 8, 2020, the board of directors of Emmaus Life Sciences, Inc. ("Emmaus" or the "Company"), based on the recommendation of the audit committee concluded, that due to errors identified
Dec 10, 2020 10:30 am ET
Michigan Revises Prior Authorization Criteria for Endari®
TORRANCE, Calif., Dec. 10, 2020 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTC: EMMA), a leader in the treatment of sickle cell disease, announced today that it was notified by the Michigan Department of Health and Human Services (MDHHS) that the prior authorization criteria for Endari® was revised after being reviewed by Michigan's Medicaid Health Plan Common Formulary Workgroup. The MDHHS created the common formulary to streamline drug coverage policies for Medicaid and Healthy Michigan Plan beneficiaries and providers.
Dec 08, 2020 10:30 am ET
Emmaus Life Sciences Launches Endari® Support Program
TORRANCE, Calif., Dec. 8, 2020 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTC: EMMA), a leader in the treatment of sickle cell disease, announced today the launch of the Endari® Support Program. The Program is intended to provide patients who are unable to afford Endari® access to the medication for minimal or no-cost. Emmaus has partnered with Lash Group's TheraCom Specialty Pharmacy, a part of AmerisourceBergen Corporation, to fill prescriptions for Endari® and administer the Program.
Dec 03, 2020 10:20 am ET
Endari® Granted Orphan Drug Status in Switzerland
TORRANCE Calif., Dec. 3, 2020 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTC: EMMA), a leader in the treatment of sickle cell disease, announced today that the Swiss Agency for Therapeutic Products (Swissmedic) has granted orphan drug status to Endari®. Orphan drug status (ODS) is available to medicinal products that treat conditions affecting no more than 5 out of 10,000 people in Switzerland or that have been granted ODS or its equivalent in another country with comparable medicinal product controls.  Endari® also enjoys Orphan Drug status and Orphan Medicinal status in the United States
Nov 10, 2020 10:25 am ET
Emmaus Life Sciences Submits Temporary License Application in Bahrain for Endari®
TORRANCE, Calif., Nov. 10, 2020 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTC: EMMA), a leader in the treatment of sickle cell disease, announced today that it has submitted a temporary license application for Endari® to the National Health Regulatory Authority in the Kingdom of Bahrain. Approval of the temporary application takes one to two months and is a prerequisite for Marketing Authorization Approval (MAA). Upon approval of the temporary license application, Emmaus will apply for MAA, which typically takes twelve months. The temporary license will allow Endari® to be prescribed in Ba
Nov 03, 2020 10:30 am ET
FDA Approves Updated Label for Endari®
TORRANCE, Calif., Nov. 3, 2020 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTC: EMMA), a leader in sickle cell disease treatment, announced today revised prescribing information for Endari® to better inform healthcare professionals and sickle cell disease patients. Based on approval from the FDA, the updated label includes a statement that the clinical benefit of Endari® was observed irrespective of hydroxyurea usage and a new step-by-step instruction for use section at the end of the prescribing information.
Sep 01, 2020 08:00 am ET
Emmaus Life Sciences Announces Informational Stockholders Meeting
Emmaus Life Sciences, Inc. (OTCPK: EMMA), a leader in sickle cell disease  treatment, announced today that it will hold an informational meeting of stockholders at which management will provide an update on recent sales activities and other...
Aug 18, 2020 01:41 pm ET
UPDATE - Emmaus Life Sciences Announces Submission of Marketing Authorization Application to the Saudi Food and Drug Authority
Emmaus Life Sciences, Inc. (OTCPK: EMMA), a leader in sickle cell disease treatment, announced today the submission of an application to the Saudi Food and Drug Authority (SFDA) for Marketing Authorization (MA) for Endari® in the Kingdom of Saudi...
Aug 18, 2020 08:00 am ET
Emmaus Life Sciences Announces Submission of Marketing Authorization Application to the Saudi Food and Drug Authority
Emmaus Life Sciences, Inc. (OTCPK: EMMA), a leader in sickle cell disease treatment, announced today the submission of an application to the Saudi Food and Drug Authority (SFDA) for Marketing Authorization (MA) for Endari® in the Kingdom of Saudi...
Aug 05, 2020 08:00 am ET
Emmaus Life Sciences Reports Additional Positive Preliminary Results in Diverticulosis Pilot Trial
Emmaus Life Sciences, Inc. (OTCPK: EMMA), a leader in sickle cell disease treatment, announced today preliminary top-line data for two patients who most recently completed the first six months of the scheduled twelve months of treatment in a pilot...
Jul 31, 2020 08:00 am ET
Emmaus Life Sciences Provides Additional Operational and OTC Markets Updates
Emmaus Life Sciences, Inc. (OTCQB: EMMA), a leader in sickle cell disease treatment, provided today additional operational updates for the year ended December 31, 2019 as well as operational updates for the quarters ended March 31 and June 30, 2020...
Jul 29, 2020 12:10 pm ET
Emmaus Life Sciences Receives Scientific Advice From the EMA Regarding Xyndari™
Emmaus Life Sciences, Inc. (OTCQB: EMMA), a leader in sickle cell disease treatment, announced today that the European Medicines Agency (EMA) issued scientific advice to Emmaus regarding the clinical development pathway for Xyndari™ for the...
Jul 23, 2020 01:14 pm ET
Emmaus Life Sciences Accelerates Middle East and North Africa (MENA) Growth Strategy with Opening of its Dubai Office
Emmaus Life Sciences, Inc. (OTCQB: EMMA), a leader in sickle cell disease treatment, announced today the opening of its regional office in Dubai. The Dubai office will be utilized to enhance Emmaus’ relationships with clinicians and patient groups...
Jul 16, 2020 08:00 am ET
Emmaus Life Sciences Announces Engagement of Partner International to Lead Out-Licensing of Endari® for Diverticulosis
Emmaus Life Sciences, Inc. (OTCQB: EMMA), a leader in sickle cell disease   treatment, is pleased to announce that it has engaged Partner International to lead the out-licensing activity for Emmaus’ prescription grade L-glutamine (PGLG) oral powder...
Jul 08, 2020 04:05 pm ET
Emmaus Life Sciences to Restate Previously Issued Financial Statements
Emmaus Life Sciences, Inc. (OTCQB: EMMA), a leader in sickle cell disease treatment, today announced it will be restating its previously issued audited consolidated financial statements for the twelve months ended December 31, 2018 and unaudited...
Jun 29, 2020 08:00 am ET
Emmaus Life Sciences Receives Endari® Marketing Authorization from the Israeli Ministry of Health
Emmaus Life Sciences, Inc. (OTCQB: EMMA), a leader in sickle cell disease treatment, announced today that it was issued a license from the Israeli Ministry of Health on June 17, 2020 granting marketing authorization for the commercial distribution...
Jun 25, 2020 08:00 am ET
National Institutes of Health Announces Intention with Respect to Grant of Exclusive Patent License to Emmaus Life Sciences
Emmaus Life Sciences, Inc. (OTCQB: EMMA), a leader in sickle cell disease treatment, today reported that on June 22, 2020 the National institutes of Health (NIH) issued a Notice that the National Cancer Institute, an institute of the NIH,...
Jun 02, 2020 08:00 am ET
Emmaus Life Sciences Provides Operational Updates
Emmaus Life Sciences, Inc. (OTCQB: EMMA), a leader in sickle cell disease treatment, provided today operational updates in advance of the filing of its 10-K for the year ended December 31, 2019 and its 10-Q for the first quarter of 2020. “We look...
Apr 27, 2020 08:00 am ET
APCER Report Confirms Endari® Safety
Emmaus Life Sciences, Inc. (OTCQB: EMMA), a leader in sickle cell disease treatment, announced today that APCER Life Sciences (APCER) has confirmed the safety profile of Endari®, Emmaus’ prescription grade L-glutamine oral powder for the treatment...
Apr 16, 2020 08:00 am ET
Emmaus Life Sciences Announces SFDA (Saudi Food & Drug Authority) Accepts Endari® Priority Review Request
Emmaus Life Sciences, Inc. (OTCQB: EMMA), a leader in sickle cell disease  treatment, announced today that the SFDA (Saudi Food & Drug Authority) has accepted its request for priority review of Endari®, its prescription grade L-glutamine oral...
Mar 30, 2020 09:16 am ET
Life Sciences Companies Investors Presentations Now Available for On-Demand Viewing
Life Sciences Investor Forum today announced that the presentations from its inaugural conference are now available for on-demand viewing at LifeSciencesInvestorForum.com. This virtual event showcased live company presentations and...
Mar 24, 2020 08:30 am ET
Virtual Conference for Life Sciences Companies and Investors Broadcast Live March 26, 2020
Life Sciences Investor Forum today announced the agenda for its inaugural event for public and private companies, investors and industry professionals from around the world. This day-long virtual event will showcase live company presentations and...
Mar 24, 2020 08:00 am ET
Emmaus Life Sciences Provides Update in Response to the Coronavirus (COVID-19) Pandemic
Emmaus Life Sciences, Inc. (OTCQB: EMMA), a leader in sickle cell disease (SCD) treatment, announced today several steps it has taken in response to the Coronavirus (COVID-19) pandemic. Within the overall SCD community, Emmaus is working in...
Mar 23, 2020 08:35 am ET
Emmaus Life Sciences to Webcast Live at Life Sciences Investor Forum March 26th
Emmaus Life Sciences, Inc. (OTCQB:EMMA), a leader in sickle cell disease treatment, today announced that Dr. Yutaka Niihara, M.D., M.P.H., Chairman and Chief Executive Officer, and Jay Sherwood, Chief Financial Officer, will present live at...
Mar 03, 2020 08:00 am ET
Emmaus Life Sciences Announces Equity Purchase Agreement for up to $25 Million with Lincoln Park Capital
Emmaus Life Sciences, Inc. (OTCQB: EMMA), a leader in sickle cell disease  treatment, announced today the execution of a purchase agreement for up to $25 million of common stock with Lincoln Park Capital Fund, LLC (“LPC”), a long-only Chicago-based...
Feb 05, 2020 08:00 am ET
Emmaus Life Sciences Reports Preliminary Gross Sales for the Three Months Ended December 31, 2019
Emmaus Life Sciences, Inc. (OTCQB: EMMA), a leader in sickle cell disease (SCD) treatment, today reported preliminary gross sales of $7.8 million for the fourth quarter ended December 31, 2019 representing an 11.4% increase over gross sales of $7.0...
Jan 29, 2020 08:00 am ET
Emmaus Life Sciences Reports Positive Top-Line Preliminary Results in First Patient in Diverticulosis Pilot Trial
Emmaus Life Sciences, Inc. (OTCQB: EMMA), a leader in sickle cell disease treatment, announced today the top-line preliminary results in the first patient in the company’s Pilot/Phase 1 study in the treatment of diverticulosis. The study is...
Jan 27, 2020 08:00 am ET
Emmaus Life Sciences Expresses Concerns Over Inaccuracies in Draft Report Issued by ICER (Institute for Clinical and Economic Review)
Emmaus Life Sciences, Inc. (OTCQB: EMMA), a leader in sickle cell disease treatment, responded today to the draft evidence report by ICER dated January 23, 2020 examining the effectiveness and value of Crizanlizumab, Voxelotor, and L-glutamine in...
Jan 06, 2020 08:00 am ET
Emmaus Life Sciences Announces a New Adherence Program for Its Sickle Cell Disease Patients
Emmaus Life Sciences, Inc. (OTCQB: EMMA), a leader in sickle cell disease treatment, is pleased to announce a new adherence program available to sickle cell disease (SCD) patients in collaboration with US Bioservices, an AmerisourceBergen specialty...
Dec 31, 2019 04:01 pm ET
Emmaus Life Sciences Announces First Purchase Order from its Partnership with taiba Healthcare
Emmaus Life Sciences, Inc. (OTCQB: EMMA), a leader in sickle cell disease treatment, today reported that it received the initial purchase order relating to taiba Healthcare’s early access program for Endari® (L-glutamine oral powder) in Oman. Based...
Dec 23, 2019 04:01 pm ET
Emmaus Life Sciences Announces Update of its Partnership with taiba Healthcare to Expand Patient Access for Sickle Cell Disease Treatment in the Middle East and North Africa (MENA) Region
Emmaus Life Sciences, Inc. (OTCQB: EMMA), a leader in sickle cell disease treatment, today reported that it expects to receive shortly the initial purchase orders relating to taiba Healthcare’s early access program for Endari® (L-glutamine oral...
Nov 12, 2019 08:00 am ET
Emmaus Life Sciences Reports 2019 Third Quarter Financial Results
Emmaus Life Sciences, Inc. (OTCQB: EMMA), a leader in sickle cell disease treatment, today reported continuing growth and improved financial results for the quarter and nine-months ended September 30, 2019.  2019 Third Quarter Financial ResultsNet...
Oct 29, 2019 08:00 am ET
Emmaus Life Sciences Announces Equity Investment from a Corporate Investor
Emmaus Life Sciences, Inc. (OTCQB: EMMA), a leader in sickle cell disease treatment, today reported that Vivozon, Inc. has executed a stock purchase agreement for the purchase of 800,000 shares of Emmaus common stock at $3.00 per share for a total...
Oct 11, 2019 08:00 am ET
Emmaus Life Sciences Reports Preliminary Gross Sales for the Three Months Ended September 30, 2019
Emmaus Life Sciences, Inc. (OTCQB: EMMA), a leader in sickle cell disease (SCD) treatment, today reported preliminary gross sales results of $7.0 million for the third quarter ended September 30, 2019 compared to $6.2 million for the second quarter...
Oct 09, 2019 07:30 am ET
Emmaus Life Sciences Granted Patent in India for use of Pharmaceutical-grade L-glutamine in Treating Diverticulosis
Emmaus Life Sciences, Inc. (OTCQB: EMMA), a leader in sickle cell disease treatment, announced today the allowance by the Indian Patent Office of its patent application (serial number 1255/KOLNP/2014) for methods and compositions of...
Sep 26, 2019 08:00 am ET
Emmaus Life Sciences Announces its Common Stock to Begin Trading on OTCQB September 26
TORRANCE, Calif., Sept. 26, 2019 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQB: EMMA), a leader in sickle cell disease treatment, today announced it is approved to have its common stock trade on the OTCQB marketplace, effective September 26, 2019. The common stock of Emmaus was previously quoted on OTC Link® as OTC Pink.
Sep 24, 2019 07:00 am ET
Emmaus Life Sciences Reinforces Positive Outcomes of Endari ® Clinical Trials, Including Efficacy Findings That Led to FDA Approval
TORRANCE, Calif., Sept. 24, 2019 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTC: EMMA), a leader in sickle cell disease (SCD) treatment, today released the following summary review of the clinical trials and efficacy findings for Endari®.
Sep 19, 2019 04:05 pm ET
Emmaus Life Sciences Announces Withdrawal of Marketing Authorization Application to European Medicines Agency
TORRANCE, Calif., Sept. 19, 2019 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTC: EMMA), a leader in sickle cell disease treatment, today announced the withdrawal of its marketing authorization application (MAA) to the European Medicines Agency (EMA) for Xyndari™ (glutamine) for the treatment of sickle cell disease.
Sep 18, 2019 07:00 am ET
Emmaus Life Sciences Huddles Up with SCDAAMI to Host "Sideline Sickle Cell" Community Town Hall in Detroit
TORRANCE, Calif., Sept. 18, 2019 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTC: EMMA), a leader in sickle cell disease treatment, announced today that the company's Sideline Sickle Cell campaign, led by Emmy Award-winning NFL broadcaster Solomon Wilcots, will host a sickle cell disease (SCD) community town hall in Detroit with the SCDAAMI to raise awareness of the rare disease and discuss current and future therapeutics.
Sep 10, 2019 08:00 am ET
Emmaus Life Sciences to be Delisted from Nasdaq Stock Market Following Hearing
TORRANCE, Calif., Sept. 10, 2019 /PRNewswire/ -- Emmaus Life Sciences, Inc. (Nasdaq: EMMA), a leader in sickle cell disease treatment, announced today that it was informed yesterday that the Nasdaq Hearings Panel had declined to reverse the Nasdaq Listing Qualification's decision to delist Emmaus common stock and warrants. As a result, Emmaus common stock and warrants will be delisted from The Nasdaq Stock Market at the start of trading on Wednesday, September 11, 2019. It is expected that the company's common stock and warrants will be eligible for quotation on the OTC market after that
Sep 03, 2019 08:30 am ET
Emmaus Life Sciences Granted European Patent for use of Pharmaceutical-grade L-glutamine in Treating Diverticulosis
TORRANCE, Calif., Sept. 3, 2019 /PRNewswire/ -- Emmaus Life Sciences, Inc. (Nasdaq: EMMA), a leader in sickle cell disease treatment, announced today the allowance of patent application number 12860587.0, directed to the treatment of diverticulosis, by the European Patent Office. The allowance of this application follows the issuance of corresponding patents in the United States, Japan, Australia, Mexico, China, Indonesia, South Korea and Russia. Patent applications are currently pending in various jurisdictions around the world, including Brazil and India.
Aug 28, 2019 02:16 pm ET
Emmaus Life Sciences Adds Oncology Supply as Distributor
TORRANCE, Calif., Aug. 28, 2019 /PRNewswire/ -- Emmaus Life Sciences, Inc. (Nasdaq: EMMA), a leader in sickle cell disease treatment, announced today the addition of Oncology Supply, a part of Amerisource Bergen, as a distributor of its signature product, Endari® (L-glutamine oral powder).
Aug 14, 2019 07:00 am ET
Emmaus Life Sciences to Host "Sideline Sickle Cell" Community Town Hall with ASAP and FSCDR in South Florida
TORRANCE, Calif., Aug. 14, 2019 /PRNewswire/ -- Emmaus Life Sciences, Inc. (Nasdaq: EMMA), a leader in sickle cell disease treatment, announced today that the company's Sideline Sickle Cell campaign, led by Emmy Award-winning NFL broadcaster Solomon Wilcots, will host a sickle cell disease (SCD) community town hall in South Florida to raise awareness for the rare disease and discuss current and future therapeutics.
Aug 12, 2019 08:00 am ET
Emmaus Life Sciences Reports Sharply Improved 2019 Second Quarter Financial Results
TORRANCE, Calif., Aug. 12, 2019 /PRNewswire/ -- Emmaus Life Sciences, Inc. (Nasdaq: EMMA), a leader in sickle cell disease treatment, today reported significantly improved financial results at its EMI Holding, Inc. (EMI) subsidiary for the 2019 second quarter and six-months ended June 30, 2019.  EMI is the company's principal operating subsidiary.
Aug 08, 2019 03:51 pm ET
Emmaus Life Sciences Reiterates Financial Benefits from Recent Merger
TORRANCE, Calif., Aug. 8, 2019 /PRNewswire/ -- Emmaus Life Sciences, Inc. (Nasdaq: EMMA), a leader in sickle cell disease treatment, today reiterated the improved balance sheet, reduced debt service and other benefits realized from its recently completed merger transaction announced on July 17, 2019.
Jul 29, 2019 08:00 am ET
Emmaus Life Sciences Details Financial Benefits from Recent Merger, including Improved Balance Sheet and Reduced Debt Service
TORRANCE Calif., July 29, 2019 /PRNewswire/ -- Emmaus Life Sciences, Inc. (Nasdaq: EMMA), a leader in sickle cell disease treatment, today detailed the improved balance sheet, reduced debt service and other benefits realized from its recently completed merger transaction announced on July 17, 2019.
Jul 22, 2019 04:05 pm ET
Emmaus Life Sciences Receives Notice of Nasdaq Delisting Following Merger with MYnd Analytics
TORRANCE, Calif., July 22, 2019 /PRNewswire/ -- Emmaus Life Sciences, Inc. (Nasdaq: EMMA), a leader in sickle cell disease treatment, announced today that it received a notice (the "Notice") from the Listing Qualifications Staff of The Nasdaq Stock Market indicating that the company is not compliant with the $5 million minimum stockholders' equity requirement under Nasdaq Listing Rule 5550(b)(1) (the "Minimum Stockholders' Equity Requirement") for continued listing of Emmaus common stock on The Nasdaq Capital Market.  The Notice also indicated that the company  is not compliant with the 400
Jul 18, 2019 10:42 am ET
Telemynd Provides Update Following Spinoff Transaction from Emmaus Life Sciences, Formerly MYnd Analytics
Telemynd, Inc., a predictive analytics company aimed at improving the delivery of mental health services through the combination of telemedicine and data analytics, today provide a business update following its spinoff from Emmaus Life Sciences,...
Jul 17, 2019 06:51 pm ET
Emmaus Life Sciences Completes Merger
TORRANCE Calif., July 17, 2019 /PRNewswire/ -- Emmaus Life Sciences, Inc., a leader in sickle cell disease treatment, and MYnd Analytics, Inc. announced today that they have completed the previously announced merger transaction, following stockholder approval by both companies on July 9.  The effective time of the merger was 6:00 P.M., Eastern time, today.

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.